ALXN2220

DRUG4 trials

Sponsors

Alexion Pharmaceuticals, Inc., Neurimmune AG, AstraZeneca

Conditions

Amyloid Transthyretin CardiomyopathyTransthyretin Amyloid CardiomyopathyTransthyretin Amyloid Cardiomyopathy (ATTR-CM)

Phase 2

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

Active, not recruitingNCT07213583

Neurimmune AGAmyloid Transthyretin Cardiomyopathy

Start: 2025-08-28End: 2026-10-31Target: 35Updated: 2025-12-19

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Active, not recruitingNCT07608354

AstraZenecaTransthyretin Amyloid Cardiomyopathy (ATTR-CM)

Start: 2026-06-11End: 2029-02-06Target: 326Updated: 2026-07-14

Phase 3

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Active, not recruitingNCT06183931

Alexion Pharmaceuticals, Inc.Transthyretin Amyloid Cardiomyopathy

Start: 2024-01-11End: 2028-04-05Updated: 2026-08-10

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

Not yet recruitingNCT07789483

Alexion Pharmaceuticals, Inc.Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Start: 2027-11-23End: 2030-07-11Target: 1180Updated: 2026-08-27